Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Interim 2017/18 influenza seasonal vaccine effectiveness:Combined results from five European studies / Rondy, ., Kissling, M., Emborg, E., Gherasim, H., Pebody, A., Trebbien, R., Pozo, R., Larrauri, F., Mcmenamin, A., Valenciano, J., Kaic, M., Filipovic, B., Visekruna-Vucina, S.K., Novosel, V., Lovric, I.P., Petrović, Z.i., Krause, G., Fische, T.G., Lina, T.K., Falchi, B., et al.. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 23:9(2018), pp. 1-12. [10.2807/1560-7917.ES.2018.23.9.18-00086]
Interim 2017/18 influenza seasonal vaccine effectiveness:Combined results from five European studies
P. AFFANNIMembro del Collaboration Group
;
2018-01-01
Abstract
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


